Published in Immunol Cell Biol on November 28, 2006
Retracted Association between polymorphism of the interleukin-13 gene and susceptibility to hepatocellular carcinoma in the Chinese population. PLoS One (2015) 1.45
Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology (2010) 1.45
Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol (2011) 1.27
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol (2013) 1.07
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Metabonomic Evaluation of ZHENG Differentiation and Treatment by Fuzhenghuayu Tablet in Hepatitis-B-Caused Cirrhosis. Evid Based Complement Alternat Med (2012) 0.99
HIV and co-infections. Immunol Rev (2013) 0.92
APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol (2008) 0.89
Potential mutations associated with occult hepatitis B virus status. Hepat Mon (2014) 0.87
Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol (2015) 0.86
Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine (2009) 0.85
HBV inhibits apoB production via the suppression of MTP expression. Lipids Health Dis (2011) 0.85
Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis (2012) 0.84
Differences of excess and deficiency zheng in patients with chronic hepatitis B by urinary metabonomics. Evid Based Complement Alternat Med (2013) 0.84
Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection. Clin Exp Immunol (2015) 0.83
Crosstalk between innate and adaptive immunity in hepatitis B virus infection. World J Hepatol (2015) 0.83
Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep (2014) 0.82
MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection. Hepat Res Treat (2014) 0.82
Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach. Blood Transfus (2010) 0.81
Hepatitis B caused by a hepatitis B surface antigen escape mutant. J Gastroenterol (2008) 0.81
Computational evolutionary analysis of the overlapped surface (S) and polymerase (P) region in hepatitis B virus indicates the spacer domain in P is crucial for survival. PLoS One (2013) 0.81
Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. Hepat Mon (2016) 0.79
Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection. J Clin Microbiol (2015) 0.79
Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection. Genet Test Mol Biomarkers (2012) 0.79
Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. Cancer Gene Ther (2012) 0.78
Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci (2015) 0.78
The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunology (2016) 0.78
Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. PLoS One (2011) 0.77
Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment. Pathogens (2014) 0.77
Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin. Gastroenterol Hepatol Bed Bench (2014) 0.77
Clinical characteristics of primary Epstein Barr virus hepatitis with elevation of alkaline phosphatase and γ-glutamyltransferase in children. Yonsei Med J (2014) 0.77
Peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection. J Interferon Cytokine Res (2013) 0.76
Notch Signaling Contributes to Liver Inflammation by Regulation of Interleukin-22-Producing Cells in Hepatitis B Virus Infection. Front Cell Infect Microbiol (2016) 0.76
The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center. Bone Marrow Transplant (2016) 0.75
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene Polymorphisms and Hepatitis B Virus Infection. Jundishapur J Microbiol (2015) 0.75
Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Front Immunol (2017) 0.75
SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. Oncotarget (2017) 0.75
Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. Iran J Basic Med Sci (2016) 0.75
Cimicifuga foetida L. plus adefovir effectively inhibits the replication of hepatitis B virus in patients with chronic hepatitis B. Biomed Rep (2016) 0.75
Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol (2017) 0.75
Toll like receptor7 polymorphisms in relation to disease susceptibility and progression in Chinese patients with chronic HBV infection. Sci Rep (2017) 0.75
Gut microbiota modulate the immune effect against hepatitis B virus infection. Eur J Clin Microbiol Infect Dis (2015) 0.75
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis (2009) 2.24
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood (2007) 2.21
Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A (2010) 2.07
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis (2011) 1.77
Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis (2010) 1.63
HDAC inhibitors in HIV. Immunol Cell Biol (2011) 1.59
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50
Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS (2013) 1.46
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis (2011) 1.40
The evidence for a change in antenatal HIV screening policy in Australia. Med J Aust (2006) 1.40
Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005. Med J Aust (2008) 1.37
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis (2010) 1.33
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology (2011) 1.31
A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther (2008) 1.25
Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
Identification of lineage relationships and novel markers of blood and skin human dendritic cells. J Immunol (2012) 1.21
Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. J Infect Dis (2013) 1.18
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis (2013) 1.16
Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One (2011) 1.15
Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol (2012) 1.15
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med (2011) 1.14
Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr (2002) 1.09
Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunol Cell Biol (2003) 1.08
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples. Clin Vaccine Immunol (2006) 1.05
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis (2011) 1.05
Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol (2006) 1.04
HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep (2012) 1.04
The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS (2009) 1.04
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. J Immunol (2002) 1.01
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology (2011) 1.00
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology (2007) 1.00
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust (2007) 0.98
The search for an HIV cure: tackling latent infection. Lancet Infect Dis (2013) 0.98
Human immunodeficiency virus infection and the liver. World J Hepatol (2012) 0.98
Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection. AIDS (2014) 0.98
Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog (2013) 0.97
Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol (2010) 0.97
Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. PLoS One (2011) 0.96
Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv (2012) 0.95
Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. AIDS Behav (2013) 0.95
Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? Curr Opin HIV AIDS (2016) 0.93
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis (2013) 0.93
Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis (2013) 0.93
Finding a cure for HIV: much work to do. Ann Intern Med (2014) 0.93
Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol (2011) 0.92
Incidence of putative HIV superinfection and sexual practices among HIV-infected men who have sex with men. Sex Health (2008) 0.92
HIV and co-infections. Immunol Rev (2013) 0.92
Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS (2014) 0.92
Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. J Neurosurg (2010) 0.91
The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. Retrovirology (2007) 0.90
Experiences and expectations of participants completing an HIV cure focused clinical trial. AIDS (2015) 0.90
Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol (2009) 0.90
Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis (2013) 0.89
A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. J Virol Methods (2010) 0.89
Fatal acute varicella-zoster virus hemorrhagic meningomyelitis with necrotizing vasculitis in an HIV-infected patient. Clin Infect Dis (2009) 0.89
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology (2013) 0.88
Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS (2011) 0.88
Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol (2004) 0.88
Thymic function in severely immunodeficient HIV type 1-infected patients receiving stable and effective antiretroviral therapy. AIDS Res Hum Retroviruses (2006) 0.88
Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS (2007) 0.88
Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis (2003) 0.88
HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J Leukoc Biol (2010) 0.88
Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood (2002) 0.87
Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection. AIDS (2011) 0.87
Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis (2006) 0.87
Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitro. Retrovirology (2011) 0.87
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses (2014) 0.87
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol (2010) 0.87
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology (2008) 0.86
Hepatitis virus immune restoration disease of the liver. Curr Opin HIV AIDS (2008) 0.86
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology (2013) 0.86
Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS (2015) 0.85
HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol (2003) 0.85
The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player. Clin Immunol (2011) 0.85
HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies. J Leukoc Biol (2013) 0.85
HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. J Med Virol (2012) 0.84
Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. Eur J Immunol (2013) 0.83
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther (2010) 0.83
Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts. J Acquir Immune Defic Syndr (2005) 0.83
Antenatal screening practice for infectious diseases by general practitioners in Australia. Aust N Z J Obstet Gynaecol (2009) 0.82
Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. AIDS (2016) 0.82
The "work" of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV. AIDS Care (2009) 0.82
Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS (2015) 0.82
A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. Nucleic Acids Res (2012) 0.81